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Treatment with TNF-α (8 ng/ml) alone stimulated levels of COX-2 expression that were 211 slightly higher than the LPA-treated cells. This effect reached a peak after 4 h but was 212 not detectable after 24 h. However, when myofibroblasts were treated with LPA 213 following an overnight incubation with TNF-α, this led to a synergistic time-dependent 214 increase in COX-2 protein expression that was evident after 2 h and was dramatically 215 augmented between 4 and 8 h, followed by a decline over the 24 h time period studied 216 (Fig 1A) . 217
To determine whether the induction of COX-2 protein expression by LPA and TNF-α 218 was associated with an increase in PGE 2 production, 18Co cells were again treated with 219 LPA and TNF-α, alone and in combination, over 24 h. Cell culture supernatant was 220 collected at various times and PGE 2 levels were quantified utilizing an ELISA. As shown 221
in Fig 1B, treatment of 18Co cells with LPA stimulated low levels of PGE 2 production, 222 which correlated with the modest increase in COX-2 expression seen by Western blot 223 analysis. Treatment with TNF-α over 24 h produced a greater effect compared to LPAtreated cells, though the effect was also modest. However, exposure of 18Co cells to 225 TNF-α for 18 h followed by LPA induced a synergistic increase in the production of 226 PGE 2 that was evident after 8 h and was sustained over a 24 h time period. Thus, the pro-227 inflammatory mediators LPA and TNF-α induced synergistic COX-2 protein expression 228 that was paralleled by increases in the production of PGE 2 in human colonic 229
myofibroblasts. 230
Since the augmented expression of COX-2 protein was most apparent after 4 h, we 231 utilized this early time period to perform an additional time course experiment to fully 232 characterize the timing of COX-2 protein expression (Fig 2A) . 18Co cells were pre-233 treated overnight with TNF-α, followed by treatment with LPA over 4 h, and COX-2 234 expression was analyzed by Western blot. Under these conditions, the up-regulation of 235 COX-2 was evident after 2 h with a steady increase in protein expression between 2 and 4 236 h. Based on this experiment, 18Co cells were treated with LPA for 4 h for all subsequent 237 experiments. 238
The effect of LPA and TNF-α on the synergistic expression of COX-2 was dose-239 dependent, as seen in Fig 2B-C . In Figure 2B , 18Co cells were treated overnight with 240 TNF-α at varying concentrations (0-80 ng/ml), followed by treatment with LPA (10 μM) 241 for 4 h. Increases in COX-2 protein expression were evident at a TNF-α concentration 242 as low as 0.8 ng/ml, well within physiologic levels, and persisted at a concentration of 80 243 ng/ml. Based on this data, subsequent experiments were performed using TNF-α at a 244 concentration of 8 ng/ml, well within the range of concentrations used in other studies 245 (12, 26, 41, 61) . In Figure 2C We next determined whether TNF-α enhanced the intensity and/or duration of LPA-264 mediated PKD activation in colonic myofibroblasts. Confluent 18Co cells were treated 265 with TNF-α overnight followed by treatment with LPA, and PKD activation was 266 assessed by Western blot. In agreement with our previous results (62), TNF-α alone did 267 not induce any detectable increase in PKD phosphorylation in 18Co cells (data not 268 shown). However, overnight pre-treatment of 18Co cells with TNF-α  enhanced LPA-269 mediated PKD activation at 15, 30, and 60 min (Fig 3) . These experiments demonstratethat TNF-α augments the intensity of LPA-mediated PKD activation in 18Co cells, while 271 having no detectable effect on PKD activation in these cells when added alone. 272 273 PKD activation and synergistic COX-2 expression induced by LPA and TNF-α involves 274 the LPA 1 receptor and Gia 275
The biologic functions of LPA are mediated by a family of at least five different G 276 protein-coupled receptors (LPA 1-5 )(10). LPA 1 was the first LPA receptor to be 277 identified(28), and high mRNA levels are present in the colon and small intestine (27) . 278
The LPA 1 receptor is also the most widely expressed LPA receptor in the human 279 colon(10), highlighting its potential importance in LPA-mediated signaling in this organ. receptor is capable of coupling with the Giα, G 12/13 , and Gαq family of G proteins (10, 306 31). To determine which G protein subunit may be involved in the LPA-mediated 307 activation of PKD and the expression of COX-2, we used the Giα-specific inhibitor 308 pertussis toxin. Pertussis toxin is an A/B type toxin that, upon entry into a cell catalyzes 309 the ADP-ribosylation of the α subunit of G proteins, locking Giα in an inactive state on 310 the cell surface. 18Co cells were treated overnight with TNF-α followed by LPA for 4 h, 311 with or without a 2 h pre-treatment with pertussis toxin (PTx), at various concentrations 312 (0-50 ng/ml). As shown in Fig 4B, pertussis toxin inhibited both the activation of PKD 313 and the synergistic increase in COX-2 expression following treatment with TNF-α and 314 LPA in a dose-dependent fashion. These experiments demonstrate that LPA-mediated 315 PKD activation and COX-2 expression signal predominantly through Giα   and furthersupport the hypothesis that PKD may play a critical role in the synergistic expression of 317 COX-2 in colonic myofibroblasts. 318
Previous work in our laboratory demonstrated that the pro-inflammatory mediator 319 bradykinin (BK) also induced PKD activation and synergistic COX-2 expression in 320 response to TNF-α in 18Co cells (62). However, bradykinin-induced PKD activation and 321 COX-2 expression signals predominantly through Gαq. To confirm the specificity of 322 pertussis toxin on the inhibition of Giα, and to distinguish the upstream signaling 323 mechanisms initiated by bradykinin and LPA, 18Co cells were treated overnight with 324 TNF-α followed by bradykinin for 4 h, with or without a 2 h pre-treatment with pertussis 325 toxin (PTx), at various concentrations (0-50 ng/ml). In stark contrast to its effect on 326 LPA, the Giα-specific inhibitor pertussis toxin failed to inhibit BK-mediated COX-2 327 expression and BK-mediated PKD phosphorylation at all concentrations used (Fig 4C) . 328
This data further supports the predominant role of Giα, and not other G proteins, in LPA-329 mediated COX-2 expression and PKD activation. 330
LPA-mediated PKD activation and synergistic COX-2 expression involves PKC. 331
Isoforms of the PKC family are major downstream targets of LPA-mediated signaling 332 in other cell systems(8). Furthermore, both the LPA 1 receptor and Giα propagate 333 signaling cascades that can result in the activation of phospholipase C (PLC) and its 334 downstream target PKC(10). Therefore, we sought to determine the role of PKC, and 335 possibly its downstream target PKD, in the synergistic expression of COX-2 in response 336 to LPA and TNF-α in colonic myofibroblasts. Cultures of 18Co cells were incubated 337 overnight with TNF-α, then were pre-treated for 60 min with the preferential PKC 338 inhibitors GF109203X (also known as bisindolylmaleimide I) at 5μM or Go6983 339 (2.5μM), prior to stimulation with LPA for 4 h. Cell treatment with either Go6983 or 340 GF109203X completely inhibited both the augmented activation of PKD and the 341 synergistic expression of COX-2 induced by LPA and TNF-α (Fig. 5A) . In a parallel 342 fashion, Go6983 and GF109203X also blocked LPA and TNF-α mediated PGE 2 343 production, as quantified by ELISA (Fig 5B) . These results suggest that PKC isoforms 344 play an upstream role in both LPA-mediated PKD activation, and in the synergistic 345 enhancement of COX-2 expression and PGE 2 production mediated by TNF-α and LPA. The importance of LPA in the development and progression of cancer was supported by 384 the discovery that autotaxin, an ecto-enzyme known to promote tumor invasion and 385 metastasis, acts by producing bioactive LPA extracellularly in the tumor 386 microenvironment(27). LPA has been linked to ovarian, prostate, gastric and colorectal 387 cancer (10, 23, 44, 65) , as well as to the production of COX-2 and prostaglandin secretion 388 (23, 30) by stromal cells of the gastrointestinal tract (59). 389
The present study identifies a possible mechanism for the association between LPA-390 mediated signaling, inflammation, and cancer development. We found synergistic effects 391 between LPA and TNF-α resulting in the amplification of COX-2 expression and PGE 2production through a conserved PKD-dependent signaling mechanism that appears to 393 predominantly involve the LPA 1 receptor and the Giα protein subunit leading to 394 augmented COX-2 expression in human colonic myofibroblasts. 395
The biologic activity of LPA is tightly controlled by its production and degradation, 396 but is also regulated by cross talk signaling between other pro-inflammatory mediators 397 such as TNF-α. Evidence for cross talk between TNF-α and GPCR-mediated signaling 398 exists (6, 15, 19, 62) . Our laboratory previously identified signaling interactions between 399 TNF-α and the specific GPCR bradykinin, which also led to augmented COX-2 400 expression in colonic myofibroblasts through a PKD-dependent process (62). However, 
